Your browser doesn't support javascript.
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.
Xin, Qianqian; Wu, Qianhui; Chen, Xinhua; Han, Bihua; Chu, Kai; Song, Yan; Jin, Hui; Chen, Panpan; Lu, Wanying; Yang, Tuantuan; Li, Minjie; Zhao, Yuliang; Pan, Hongxing; Yu, Hongjie; Wang, Lin.
  • Xin Q; Sinovac Biotech, Beijing, China.
  • Wu Q; School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
  • Chen X; School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
  • Han B; Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
  • Chu K; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Song Y; Suining County Center for Disease Control and Prevention, Jiangsu, China.
  • Jin H; Renqiu Center for Disease Control and Prevention, Hebei, China.
  • Chen P; Renqiu Center for Disease Control and Prevention, Hebei, China.
  • Lu W; School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
  • Yang T; Sinovac Biotech, Beijing, China.
  • Li M; Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China. liminjie507@163.com.
  • Zhao Y; Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China. yuliang_zh1@163.com.
  • Pan H; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. panhongxing@126.com.
  • Yu H; School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. yhj@fudan.edu.cn.
  • Wang L; Sinovac Life Sciences, Beijing, China. wanglin@sinovac.com.
Nat Commun ; 13(1): 3100, 2022 06 03.
Article in English | MEDLINE | ID: covidwho-1931403
ABSTRACT
Determining the duration of immunity induced by booster doses of CoronaVac is crucial for informing recommendations for booster regimens and adjusting immunization strategies. In two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, immunogenicity and safety of four immunization regimens are assessed in adults aged 18 to 59 years and one immunization regimen in adults aged 60 years and older, respectively. Serious adverse events occurring within 6 months after booster doses are recorded as pre-specified secondary endpoints, geometric mean titres (GMTs) of neutralising antibodies one year after the 3-dose schedule immunization and 6 months after the booster doses are assessed as pre-specified exploratory endpoints, GMT fold-decreases in neutralization titres are assessed as post-hoc analyses. Neutralising antibody titres decline approximately 4-fold and 2.5-fold from day 28 to day 180 after third doses in adults aged 18-59 years of age and in adults aged 60 years and older, respectively. No safety concerns are identified during the follow-up period. There are increases in the magnitude and duration of humoral response with homologous booster doses of CoronaVac given 8 months after a primary two-dose immunization series, which could prolong protection and contribute to building our wall of population immunity. Trial number NCT04352608 and NCT04383574.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-30864-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-30864-w